Image placeholder title

Sarclisa (isatuximab) – Anti CD38 Targeted Therapy for Myeloma

Sarclisa precision cancer medicine improves survival in advanced Multiple Myeloma - leads to FDA approval

Image placeholder title

COVID-19 Vaccination in Patients with Blood Cancers

Studies of COVID-19 vaccine effectiveness in myeloma and lymphoma available - vaccine relatively ineffective.

Image placeholder title

Xpovio - Selinexor Approved by FDA for the Treatment of Multiple Myeloma

Xpovio treatment of Multiple Myeloma receives FDA approval - combination appears superior to Vd with less neuropathy.